Torrent Group's pharma major - branded generics in India, Brazil & Germany; generics in the US
Price
Market Cap
Sector
Healthcare
Rank
| Line item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | FY26 |
|---|---|---|---|---|---|---|---|---|
| LiabilitiesEquity Capital | 85 | 85 | 85 | 169 | 169 | 169 | 169 | 169 |
| Reserves | 4.7k | 5.8k | 5.9k | 6.0k | 6.7k | 7.4k | 8.3k | 8.2k |
| Borrowings | 5.8k | 4.9k | 4.1k | 5.4k | 4.0k | 3.2k | 2.8k | 15.0k |
| Other Liabilities | 3.4k | 3.4k | 2.9k | 3.0k | 3.6k | 3.6k | 4.2k | 20.2k |
| Total Liabilities | 14.0k | 14.1k | 12.9k | 14.6k | 14.5k | 14.4k | 15.5k | 43.6k |
| AssetsFixed Assets | 7.5k | 7.1k | 6.4k | 8.1k | 8.1k | 7.9k | 7.8k | 33.2k |
| CWIP | 712 | 889 | 630 | 765 | 361 | 478 | 488 | 641 |
| Investments | 2 | 181 | 226 | 199 | 173 | 156 | 133 | 948 |
| Other Assets | 5.8k | 5.9k | 5.6k | 5.5k | 5.8k | 5.8k | 7.1k | 8.8k |
| Total Assets | 14.0k | 14.1k | 12.9k | 14.6k | 14.5k | 14.4k | 15.5k | 43.6k |
| Line item | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|
| ActivitiesCash from Operating | 1.8k | 1.4k | 2.0k | 1.8k | 2.4k | 3.3k | 2.6k | 3.0k |
| Cash from Investing | -246 | 229 | -444 | -196 | -2.3k | -160 | -549 | -12.6k |
| Cash from Financing | -1.3k | -1.5k | -1.7k | -1.8k | 77 | -2.8k | -2.3k | 10.2k |
| SummaryCapital Expenditure | — | — | — | — | — | — | — | — |
| Free Cash Flow | 1.1k | 990 | 1.7k | 1.6k | 2.0k | 3.0k | 2.0k | 2.4k |
| FCF Margin | — | — | — | — | — | — | — | — |
For capital-heavy businesses (telecom, power, heavy manufacturing) reported profit ignores the cash needed just to stand still. We'd systematically overvalue it, so we don't show a number.
TORNTPHARM · CAPITAL_INTENSIVE
Guides on how to read this kind of business and the numbers that matter.